HER2 Antibody-Drug Conjugates Are Active against Desmoplastic Small Round Cell Tumor.

Autor: Zhang T; New York Medical College, Valhalla, New York.; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Febres-Aldana CA; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York., Liu Z; Department of Pathology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China., Dix JM; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Cheng R; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.; Renaissance School of Medicine, Stony Brook University, Stony Brook, New York., Dematteo RG; Department of Pharmacy, Memorial Sloan Kettering Cancer Center, New York, New York., Lui AJW; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.; Cancer Research UK, University of Cambridge, Cambridge, United Kingdom., Khodos I; Antitumor Assessment Core Facility, Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York., Gili L; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Mattar MS; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Lisanti J; Antitumor Assessment Core Facility, Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York., Kwong C; Antitumor Assessment Core Facility, Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York., Linkov I; Pathology Core Facility, Memorial Sloan Kettering Cancer Center, New York, New York., Tipping MJ; Molecular Cytology Core Facility, Memorial Sloan Kettering Cancer Center, New York, New York., de Stanchina E; Antitumor Assessment Core Facility, Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York., Odintsov I; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts., Ladanyi M; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York., Somwar R; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Oct 15; Vol. 30 (20), pp. 4701-4713.

Author Correction: Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations.

Autor: Miyazaki I; Taiho Pharmaceutical Co. Ltd., Tsukuba, Japan. isao-miyazaki@taiho.co.jp., Odintsov I; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Ishida K; Taiho Pharmaceutical Co. Ltd., Tsukuba, Japan., Lui AJW; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK., Kato M; Taiho Pharmaceutical Co. Ltd., Tsukuba, Japan., Suzuki T; Taiho Pharmaceutical Co. Ltd., Tsukuba, Japan., Zhang T; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Wakayama K; Taiho Pharmaceutical Co. Ltd., Tsukuba, Japan., Kurth RI; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Cheng R; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Fujita H; Taiho Pharmaceutical Co. Ltd., Tsukuba, Japan., Delasos L; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA., Vojnic M; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Northwell Health Cancer Institute, Lenox Hill Hospital, New York, NY, USA., Khodos I; Antitumor Assessment Core Facility, Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Yamada Y; Taiho Pharmaceutical Co. Ltd., Tsukuba, Japan., Ishizawa K; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Education and Support for Regional Medicine, Tohoku University Hospital, Sendai, Japan., Mattar MS; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Funabashi K; Taiho Pharmaceutical Co. Ltd., Tsukuba, Japan., Chang Q; Antitumor Assessment Core Facility, Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Ohkubo S; Taiho Pharmaceutical Co. Ltd., Tsukuba, Japan., Yano W; Taiho Pharmaceutical Co. Ltd., Tsukuba, Japan., Terada R; Taiho Pharmaceutical Co. Ltd., Tsukuba, Japan., Giuliano C; Helsinn Healthcare SA, Lugano, Switzerland., Lu YC; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Bonifacio A; Helsinn Healthcare SA, Lugano, Switzerland., Kunte S; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Dana Cancer Center, Toledo, OH, USA., Davare MA; Department of Pediatrics, Oregon Health Sciences University, Portland, OR, USA., Cheng EH; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA., de Stanchina E; Antitumor Assessment Core Facility, Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Lovati E; Helsinn Healthcare SA, Lugano, Switzerland., Iwasawa Y; Taiho Pharmaceutical Co. Ltd., Tsukuba, Japan., Ladanyi M; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Somwar R; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. somwarr@mskcc.org.; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. somwarr@mskcc.org.

Publikováno v: Nature cancer [Nat Cancer] 2023 Oct; Vol. 4 (10), pp. 1526.

Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements.

Autor: Schram AM; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.; Weill Cornell Medical College, New York, New York., Odintsov I; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York., Espinosa-Cotton M; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York., Khodos I; Anti-tumor Core Facility, Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York., Sisso WJ; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York., Mattar MS; Anti-tumor Core Facility, Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York., Lui AJW; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York., Vojnic M; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York., Shameem SH; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Chauhan T; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Torrisi J; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York., Ford J; Merus N.V., Utrecht, the Netherlands., O'Connor MN; Merus N.V., Utrecht, the Netherlands., Geuijen CAW; Merus N.V., Utrecht, the Netherlands., Schackmann RCJ; Merus N.V., Utrecht, the Netherlands., Lammerts van Bueren JJ; Merus N.V., Utrecht, the Netherlands., Wasserman E; Merus N.V., Utrecht, the Netherlands., de Stanchina E; Anti-tumor Core Facility, Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York., O'Reilly EM; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.; Weill Cornell Medical College, New York, New York., Ladanyi M; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York., Drilon A; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.; Weill Cornell Medical College, New York, New York., Somwar R; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.

Publikováno v: Cancer discovery [Cancer Discov] 2022 May 02; Vol. 12 (5), pp. 1233-1247.

Novel Preclinical Patient-Derived Lung Cancer Models Reveal Inhibition of HER3 and MTOR Signaling as Therapeutic Strategies for NRG1 Fusion-Positive Cancers.

Autor: Odintsov I; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York., Mattar MS; Anti-Tumor Assessment Core Facility, Department of Pharmacology, Memorial Sloan Kettering Cancer Center, New York, New York., Lui AJW; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York., Offin M; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Kurzatkowski C; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York., Delasos L; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Khodos I; Anti-Tumor Assessment Core Facility, Department of Pharmacology, Memorial Sloan Kettering Cancer Center, New York, New York., Asher M; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York., Daly RM; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Rekhtman N; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York., de Stanchina E; Anti-Tumor Assessment Core Facility, Department of Pharmacology, Memorial Sloan Kettering Cancer Center, New York, New York., Ganji G; Research and Development, GlaxoSmithKline, Collegeville, Pennsylvania., Ladanyi M; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York. Electronic address: ladanyim@mskcc.org., Somwar R; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.

Publikováno v: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2021 Jul; Vol. 16 (7), pp. 1149-1165. Date of Electronic Publication: 2021 Apr 08.

MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with Lung Cancers Driven by ROS1 Fusions.

Autor: Sato H; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York., Schoenfeld AJ; Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Siau E; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York., Lu YC; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York., Tai H; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York., Suzawa K; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York., Kubota D; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York., Lui AJW; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York., Qeriqi B; Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, New York., Mattar M; Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, New York., Offin M; Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Sakaguchi M; Department of Cell Biology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan., Toyooka S; Department of Thoracic, Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan., Drilon A; Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Rosen NX; Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, New York., Kris MG; Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Solit D; Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, New York., De Stanchina E; Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, New York., Davare MA; Department of Pediatrics, Oregon Health & Science University, Portland, Oregon., Riely GJ; Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Ladanyi M; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York. ladanyim@mskcc.org.; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York., Somwar R; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2020 Jun 15; Vol. 26 (12), pp. 2932-2945. Date of Electronic Publication: 2020 Mar 02.